The Texas Department of State Health Services-Radiation Control Program has granted Positron's wholly owned subsidiary, Manhattan Isotope Technology (MIT), approval of its radioactive materials license amendment.
This amendment will permit MIT to receive and process solutions which contain Strontium-82 (Sr-82) and multiple other radioisotopes. Over the next six months MIT will obtain Sr-82 target solutions from foreign irradiators for final purification into active pharmaceutical ingredient grade Sr-82 at the MIT facility in Lubbock, Texas.
During proton irradiation to produce Sr-82, many other radioisotopes are co-produced. These additional isotopes are removed from Sr-82 during radiochemical processing. The previous MIT radioactive materials license was limited to two radioisotopes: Sr-82 and Sr-85. The new amended license broadens the scope of isotopes permitted on site and allows MIT greater flexibility in this validation phase, according to the Fishers, Ind.-based Positron.